257 related articles for article (PubMed ID: 35842983)
1. New insights into antiangiogenic therapy resistance in cancer: Mechanisms and therapeutic aspects.
Huang M; Lin Y; Wang C; Deng L; Chen M; Assaraf YG; Chen ZS; Ye W; Zhang D
Drug Resist Updat; 2022 Sep; 64():100849. PubMed ID: 35842983
[TBL] [Abstract][Full Text] [Related]
2. The great escape; the hallmarks of resistance to antiangiogenic therapy.
van Beijnum JR; Nowak-Sliwinska P; Huijbers EJ; Thijssen VL; Griffioen AW
Pharmacol Rev; 2015; 67(2):441-61. PubMed ID: 25769965
[TBL] [Abstract][Full Text] [Related]
3. Stem-like tumor cells involved in heterogeneous vasculogenesis in breast cancer.
Mao Y; Zhu L; Huang Z; Luo C; Zhou T; Li L; Wang G; Yang Z; Qi W; Yang X; Gao G
Endocr Relat Cancer; 2020 Jan; 27(1):23-39. PubMed ID: 31705798
[TBL] [Abstract][Full Text] [Related]
4. Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma.
Cascone T; Herynk MH; Xu L; Du Z; Kadara H; Nilsson MB; Oborn CJ; Park YY; Erez B; Jacoby JJ; Lee JS; Lin HY; Ciardiello F; Herbst RS; Langley RR; Heymach JV
J Clin Invest; 2011 Apr; 121(4):1313-28. PubMed ID: 21436589
[TBL] [Abstract][Full Text] [Related]
5. Fibrocytes: A Novel Stromal Cells to Regulate Resistance to Anti-Angiogenic Therapy and Cancer Progression.
Goto H; Nishioka Y
Int J Mol Sci; 2017 Dec; 19(1):. PubMed ID: 29286323
[TBL] [Abstract][Full Text] [Related]
6. Escaping Antiangiogenic Therapy: Strategies Employed by Cancer Cells.
Pinto MP; Sotomayor P; Carrasco-Avino G; Corvalan AH; Owen GI
Int J Mol Sci; 2016 Sep; 17(9):. PubMed ID: 27608016
[TBL] [Abstract][Full Text] [Related]
7. Angiogenesis in cancer: molecular mechanisms, clinical impact.
Eichhorn ME; Kleespies A; Angele MK; Jauch KW; Bruns CJ
Langenbecks Arch Surg; 2007 May; 392(3):371-9. PubMed ID: 17458577
[TBL] [Abstract][Full Text] [Related]
8. Antiangiogenic Therapy for Malignant Brain Tumors: Does It Still Matter?
Pellerino A; Bruno F; Soffietti R; Rudà R
Curr Oncol Rep; 2023 Jul; 25(7):777-785. PubMed ID: 37071295
[TBL] [Abstract][Full Text] [Related]
9. Granulocyte-macrophage colony-stimulating factor increases tumor growth and angiogenesis directly by promoting endothelial cell function and indirectly by enhancing the mobilization and recruitment of proangiogenic granulocytes.
Zheng Q; Li X; Cheng X; Cui T; Zhuo Y; Ma W; Zhao X; Zhao P; Liu X; Feng W
Tumour Biol; 2017 Feb; 39(2):1010428317692232. PubMed ID: 28240048
[TBL] [Abstract][Full Text] [Related]
10. Establishment of a 3D model of tumor-driven angiogenesis to study the effects of anti-angiogenic drugs on pericyte recruitment.
Qiu Y; Wang N; Guo T; Liu S; Tang X; Zhong Z; Chen Q; Wu H; Li X; Wang J; Zhang S; Ou Y; Wang B; Ma K; Gu W; Cao J; Chen H; Duan Y
Biomater Sci; 2021 Sep; 9(18):6064-6085. PubMed ID: 34136892
[TBL] [Abstract][Full Text] [Related]
11. Pericytes and vessel maturation during tumor angiogenesis and metastasis.
Raza A; Franklin MJ; Dudek AZ
Am J Hematol; 2010 Aug; 85(8):593-8. PubMed ID: 20540157
[TBL] [Abstract][Full Text] [Related]
12. Antiangiogenic therapy for cancer: an update.
Al-Husein B; Abdalla M; Trepte M; Deremer DL; Somanath PR
Pharmacotherapy; 2012 Dec; 32(12):1095-111. PubMed ID: 23208836
[TBL] [Abstract][Full Text] [Related]
13. Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer.
Welti J; Loges S; Dimmeler S; Carmeliet P
J Clin Invest; 2013 Aug; 123(8):3190-200. PubMed ID: 23908119
[TBL] [Abstract][Full Text] [Related]
14. Assessing the in vivo efficacy of biologic antiangiogenic therapies.
Wilson PM; LaBonte MJ; Lenz HJ
Cancer Chemother Pharmacol; 2013 Jan; 71(1):1-12. PubMed ID: 23053262
[TBL] [Abstract][Full Text] [Related]
15. The possible role of chemotherapy in antiangiogenic drug resistance.
Bocci G; Loupakis F
Med Hypotheses; 2012 May; 78(5):646-8. PubMed ID: 22365648
[TBL] [Abstract][Full Text] [Related]
16. Metabolic reprogramming of the ovarian cancer microenvironment in the development of antiangiogenic resistance.
Yue H; Lu X
Acta Biochim Biophys Sin (Shanghai); 2023 Apr; 55(6):938-947. PubMed ID: 37021977
[TBL] [Abstract][Full Text] [Related]
17. Biomarkers of evasive resistance predict disease progression in cancer patients treated with antiangiogenic therapies.
Pircher A; Jöhrer K; Kocher F; Steiner N; Graziadei I; Heidegger I; Pichler R; Leonhartsberger N; Kremser C; Kern J; Untergasser G; Gunsilius E; Hilbe W
Oncotarget; 2016 Apr; 7(15):20109-23. PubMed ID: 26956051
[TBL] [Abstract][Full Text] [Related]
18. Recent concepts of antiangiogenic therapy.
Konno H; Yamamoto M; Ohta M
Surg Today; 2010 Jun; 40(6):494-500. PubMed ID: 20496129
[TBL] [Abstract][Full Text] [Related]
19. A Quininib Analogue and Cysteinyl Leukotriene Receptor Antagonist Inhibits Vascular Endothelial Growth Factor (VEGF)-independent Angiogenesis and Exerts an Additive Antiangiogenic Response with Bevacizumab.
Butler CT; Reynolds AL; Tosetto M; Dillon ET; Guiry PJ; Cagney G; O'Sullivan J; Kennedy BN
J Biol Chem; 2017 Mar; 292(9):3552-3567. PubMed ID: 28035003
[TBL] [Abstract][Full Text] [Related]
20. Anti-angiogenesis in cancer therapeutics: the magic bullet.
Oguntade AS; Al-Amodi F; Alrumayh A; Alobaida M; Bwalya M
J Egypt Natl Canc Inst; 2021 Jul; 33(1):15. PubMed ID: 34212275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
